# A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

> **NCT06165809** · PHASE1 · WITHDRAWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.**

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** TQB3015 tablets

## Key facts

- **NCT ID:** NCT06165809
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor voluntarily withdraw the project.
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165809, "A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06165809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*